

GAC Group (2238 HK)

2Q23E NP to fall QoQ; Hyper margin key in 2H23

Maintain BUY. We project GAC Group's 2Q23E net profit to fall 7% QoQ to RMB 1.4bn despite strong sales volume for Aion, as we expect margin improvement to be offset by declining equity income from joint ventures (JVs) and associates. We still believe GAC is a defensive player, as we only value Aion HK\$ 60bn now. We are of the view that the profitability for the Hyper series could be key to Aion.

- We project 2Q23E net profit to fall 7% QoQ to RMB 1.4bn. Although we expect GAC's revenue to rise 52% YoY aided by Aion's strong sales volume, we project gross margin to only improve by 1.7 ppts QoQ to 4% in 2Q23E, amid heightened competition. We also project equity income from JVs and associates to fall 8% QoQ to RMB 2.7bn in 2Q23E amid the price war and declining sales volume for GAC Honda. We expect SG&A ratio to narrow QoQ in 2Q23E amid strong top-line growth. We assume impairment to be RMB 250mn in 2Q23E, although there is still risk for GAC Mitsubishi's goodwill impairment. Accordingly, we estimate GAC's net profit in 2Q23E to fall 48% YoY and 7% QoQ to RMB 1.4bn.
- We cut FY23-24E net profit by 15% and 11%. Although we have been warning investors since Oct 2022 that FY23E consensus was overstated, we continue to cut earnings forecasts for most companies. Management now counts on the Hyper series models (double-digit gross margin) to turn Aion profitable. We lower our gross margin projection for Aion to 2% in FY23E despite our sales volume forecast of 0.48mn units. We expect Aion to narrow losses significantly in FY24E and project GAC's homegrown brands (Trumpchi, Aion and research institute) to be profitable in FY25E. Our earnings cuts for FY23E and FY24E are mainly due to profitability in JVs and associates. We revise up FY25E net profit estimates by 20% to RMB 8.0bn.
- Valuation/Key risks. We use sum-of-the-parts (SOTP) valuation to factor in Aion's planned spin-off. We value Aion HK\$ 4.3 per share, based on 0.7x our revised FY24E P/S (previously 1x FY23E). We lower our price multiple to reflect its weak margins. We value HK\$ 2.7 per share for JVs and associates based on 3.0x our FY24E P/E (previously 3.0x FY23E), which is equivalent to a conservative dividend discount model assuming equity income to decline YoY significantly from FY25E and become 0 in FY30E. We value 0 for Trumpchi. Accordingly, we maintain BUY rating and lower target price slightly from HK\$ 7.50 to HK\$ 7.00. Key risks to our rating and target price include lower sales volume and margins especially for Aion and a sector de-rating.

Earnings Summary

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	75,676	110,006	137,042	145,964	155,076
YoY growth (%)	19.8	45.4	24.6	6.5	6.2
Net income (RMB mn)	7,511	7,983	5,612	6,259	8,015
EPS (RMB)	0.73	0.77	0.53	0.59	0.76
YoY growth (%)	25.9	6.3	(29.7)	11.5	28.1
P/E (x)	5.2	5.1	7.9	7.1	5.5
P/B (x)	0.4	0.4	0.4	0.4	0.3
Yield (%)	3.6	4.2	2.6	2.8	3.6
ROE (%)	8.6	7.8	4.9	5.2	6.4
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

HK\$ 7.00 **Target Price** (Previous TP HK\$ 7.50) Up/Downside +49.9% **Current Price** HK\$ 4 67

China Auto Sector

SHI Ji, CFA (852) 3761 8728 shiji@cmbi.com.hk

DOU Wenjing, CFA (852) 6939 4751 douwenjing@cmbi.com.hk

GU Sijie jasongu@cmbi.com.hk

Stock Data	
Mkt Cap (HK\$ mn)	48,960
Avg 3 mths t/o (HK\$ mn)	60
52w High/Low (HK\$)	8.18/4.40
Total Issued Shares (mn)	10,483
Source: Bloomberg	

Shareholding Structure	
Guangzhou Automobile Industry	52.5%
Others	47.5%
Source: HKEy	

Share Performance							
	Absolute	Relative					
1-mth	-0.6%	-0.5%					
3-mth	-7.2%	0.2%					
6-mth	-12.4%	-6.3%					

Source: Bloomberg



Auditor: PricewaterhouseCoopers

Related Reports

"GAC Group – 1Q23 earnings miss on gross margin" – 2 May 2023



Figure 1: Quarterly results

RMB mn	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23E	YoY	QoQ
Sales volume (units)	608,167	541,759	675,024	608,761	539,875	602,400	11.2%	11.6%
Revenue	23,268	25,421	31,678	29,639	26,557	38,640	52.0%	45.5%
Gross profit	1,025	1,160	1,470	2,320	610	1,546	33.3%	153.4%
R&D expenses	(241)	(319)	(388)	(760)	(397)	(541)	69.8%	36.2%
SG&A expenses	(2,110)	(2,287)	(2,324)	(1,676)	(1,883)	(2,434)	6.5%	29.3%
Investment Income	4,227	4,271	3,770	2,049	2,955	2,724	-36.2%	-7.8%
Operating profit	2,854	2,883	2,102	(383)	1,145	1,169	-59.4%	2.1%
Net profit	3,009	2,742	2,312	6	1,538	1,425	-48.0%	-7.3%
Gross margin	4.4%	4.6%	4.6%	7.8%	2.3%	4.0%	-0.6 ppt	1.7 ppt
Operating margin	12.3%	11.3%	6.6%	-1.3%	4.3%	3.0%	-8.3 ppt	-1.3 ppt
Net margin	12.9%	10.8%	7.3%	0.0%	5.8%	3.7%	-7.1 ppt	-2.1 ppt

Source: Company data, CMBIGM

Figure 2: Earnings revision

		New			Old			Diff (%)		
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	
Revenue	137,042	145,964	155,076	114,761	121,694	119,288	19.4%	19.9%	30.0%	
Gross profit	5,615	9,110	14,183	4,030	6,463	8,126	39.3%	41.0%	74.5%	
Operating profit	(5,773)	(3,234)	504	(5,745)	(3,592)	(1,994)	N/A	N/A	N/A	
Net profit	5,612	6,259	8,015	6,568	7,053	6,687	-14.6%	-11.3%	19.9%	
Gross margin	4.1%	6.2%	9.1%	3.5%	5.3%	6.8%	0.6 ppt	0.9 ppt	2.3 ppt	
Operating margin	-4.2%	-2.2%	0.3%	-5.0%	-3.0%	-1.7%	0.8 ppt	0.7 ppt	2.0 ppt	
Net margin	4.1%	4.3%	5.2%	5.7%	5.8%	5.6%	-1.6 ppt	-1.5 ppt	-0.4 ppt	

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

	CMBIGM				Consensus	;	Diff (%)		
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	137,042	145,964	155,076	127,690	142,866	157,731	7.3%	2.2%	-1.7%
Gross profit	5,615	9,110	14,183	8,696	11,359	13,953	-35.4%	-19.8%	1.7%
Operating profit	(5,773)	(3,234)	504	(4,975)	(4,189)	(1,052)	N/A	N/A	N/A
Net profit	5,612	6,259	8,015	8,353	8,939	9,570	-32.8%	-30.0%	-16.2%
Gross margin	4.1%	6.2%	9.1%	6.8%	8.0%	8.8%	-2.7 ppt	-1.7 ppt	0.3 ppt
Operating margin	-4.2%	-2.2%	0.3%	-3.9%	-2.9%	-0.7%	-0.3 ppt	0.7 ppt	1.0 ppt
Net margin	4.1%	4.3%	5.2%	6.5%	6.3%	6.1%	-2.4 ppt	-2.0 ppt	-0.9 ppt

Source: Bloomberg, CMBIGM estimates

Figure 4: SOTP valuation

GAC (2238 HK)	FY24E (RMB bn)	Target P/E Multiple	Target P/S Multiple	Est. Shareholding	Target Market Cap (HK\$ bn)	Target Price (HK\$)
Estimated Revenue of Aion	79	-	0.7x	75%	45	4.3
Estimated Share of Profits of Joint Ventures & Associates	9	3.0x	-	-	29	2.7
SOTP					74	7.0

Source: CMBIGM estimates



Financial Summary

Income statement					=>	Cash flow					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue	75,676	110,006	137,042	145,964	155,076	Profit before taxation	7,412	7,377	4,763	5,952	8,384
Cost of sales	(71,777)	(105,550)	(131,427)	(136,855)	(140,893)	Depreciation/amortization	5,719	6,690	7,547	8,500	9,467
Gross profit	3,899	4,457	5,615	9,110	14,183	Change in working capital	(8,134)	(9,458)	(1,997)	365	(1,948)
						Others	(11,488)	(11,246)	(9,387)	(7,705)	(6,572)
Selling exp.	(4,340)	(4,228)	(4,778)	(5,412)	(5,969)	Net cash from operating	(6,491)	(6,638)	926	7,113	9,331
Admin exp.	(4,556)	(5,487)	(7,436)	(7,951)	(8,730)						
Other gains	1,371	(1,409)	826	1,020	1,020	Capex	(6,243)	(8,014)	(9,000)	(9,100)	(9,100)
Operating profit	(3,626)	(6,668)	(5,773)	(3,234)	504	Others	13,478	6,421	9,715	7,867	5,667
						Net cash from investing	7,235	(1,592)	715	(1,233)	(3,433)
Net finance costs	(367)	(21)	(49)	51	137	•		,			• • •
Profit share of asso.&JVs	11,404	14,065	10,585	9,135	7,744	Net borrowings	2,657	6,200	(7,539)	(753)	(3,481)
Pre-tax profit	7,412	7,377	4,763	5,952	8,384	Dividend paid	(2,135)	(2,485)	(2,394)	(1,869)	(2,156)
	.,	.,	.,	0,002	0,00	Others	255	21,466	(268)	(261)	(254)
Tax	154	536	175	95	(13)	Net cash from financing	777		(10,201)	(2,883)	(5,891)
Minority interests	(55)	71	674	211	(357)	Net basii iroin iiianoiiig		20,101	(10,201)	(2,000)	(0,001)
Net profit	7, 511	7,983	5,612	6,259	8,015	Not change in each	1,520	16,950	(8,560)	2,997	7
Het pront	7,511	7,303	3,012	0,239	0,013	Net change in cash	•	-	. , ,	•	
						Cash at year beginning	15,791	17,235	34,222	25,662	28,659
						Exchange difference	(76) 17,235	37 34,222	25,662	-	20.000
						Cash at year end	17,233	34,222	25,002	28,659	28,666
Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Current assets	61,192	91,792	96,854		106,577	Sales mix (%)					
Cash & equivalents	17,235	34,222	25,662	28,659	28,666	Automobile	65.0	71.5	77.0	78.1	80.0
Account receivables	25,110	31,597	43,178	45,989	48,860	Parts and services	32.1	25.2	20.2	18.9	17.1
Inventories	8,111	12,362	14,403	14,998	15,440	Finance and others	2.9	3.2	2.9	3.0	2.9
Other current assets	10,736	13,612	13,612	13,612	13,612						
						Growth (%)					
Non-current assets	93,059	98,283	100,402	101,661	102,845	Revenue	19.8	45.4	24.6	6.5	6.2
PP&E	19,476	20,761	19,645	18,502	17,262	Gross profit	69.8	14.3	26.0	62.2	55.7
Intangibles	13,581	14,471	16,379	17,257	17,451	Operating profit	1.6	83.9	(13.4)	(44.0)	(115.6)
Deferred income tax	2,834	3,715	3,715	3,715	3,715	Net profit	25.9	6.3	(29.7)	11.5	28.1
Other non-current assets	57,168	59,335	60,663	62,187	64,416	·					
Total assets	154,251	190,075	197,257		209,422	Profit & loss ratio (%)					
	,	•	•	•	,	Gross margin	5.2	4.1	4.1	6.2	9.1
Current liabilities	49,133	56,688	61,535	64,223	61,982	Operating margin	(4.8)	(6.1)	(4.2)	(2.2)	0.3
	-	•	-	-	,		9.9	7.3	4.1	4.3	5.2
Bank harrowings	g xxu	13 813	6 / 11/1	5 /n 3		Net profit margin			7.1	7.5	0.2
Bank borrowings Account payables	9,889 38,490	13,813 42,069	6,704 54,011	5,263 58,116	1,283 59,831	Net profit margin	9.9	7.0			
Account payables	38,490	42,069	54,011	58,116	59,831		9.9	7.0			
Account payables Tax payable	38,490 202	42,069 185	54,011 185	58,116 185	59,831 185	Balance sheet ratio			0.4	0.0	0.0
Account payables	38,490	42,069	54,011	58,116	59,831	Balance sheet ratio Net cash/total equity (x)	0.1	0.1	0.1	0.2	
Account payables Tax payable Other current liabilities	38,490 202 551	42,069 185 622	54,011 185 635	58,116 185 658	59,831 185 683	Balance sheet ratio Net cash/total equity (x) Current ratio (x)	0.1 1.2	0.1 1.6	1.6	1.6	0.2 1.7
Account payables Tax payable Other current liabilities Non-current liabilities	38,490 202 551 12,469	42,069 185 622 11,084	54,011 185 635 10,075	58,116 185 658 10,582	59,831 185 683 11,111	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days	0.1 1.2 121	0.1 1.6 105	1.6 115	1.6 115	1.7 115
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings	38,490 202 551 12,469 7,527	42,069 185 622 11,084 5,697	54,011 185 635 10,075 4,697	58,116 185 658 10,582 5,197	59,831 185 683 11,111 5,697	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days	0.1 1.2 121 41	0.1 1.6 105 43	1.6 115 40	1.6 115 40	1.7 115 40
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants	38,490 202 551 12,469 7,527 2,196	42,069 185 622 11,084 5,697 2,183	54,011 185 635 10,075 4,697 2,056	58,116 185 658 10,582 5,197 1,947	59,831 185 683 11,111 5,697 1,855	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days	0.1 1.2 121	0.1 1.6 105	1.6 115	1.6 115	1.7 115 40
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants Other non-current liabilities	38,490 202 551 12,469 7,527 2,196 2,747	42,069 185 622 11,084 5,697 2,183 3,204	54,011 185 635 10,075 4,697 2,056 3,323	58,116 185 658 10,582 5,197 1,947 3,438	59,831 185 683 11,111 5,697 1,855 3,559	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days Payable turnover days	0.1 1.2 121 41	0.1 1.6 105 43	1.6 115 40	1.6 115 40	1.7 115 40
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants Other non-current liabilities	38,490 202 551 12,469 7,527 2,196	42,069 185 622 11,084 5,697 2,183	54,011 185 635 10,075 4,697 2,056	58,116 185 658 10,582 5,197 1,947	59,831 185 683 11,111 5,697 1,855	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days Payable turnover days Profitability (%)	0.1 1.2 121 41 196	0.1 1.6 105 43 145	1.6 115 40 150	1.6 115 40 155	1.7 115 40 155
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants Other non-current liabilities Total liabilities	38,490 202 551 12,469 7,527 2,196 2,747 61,602	42,069 185 622 11,084 5,697 2,183 3,204 67,772	54,011 185 635 10,075 4,697 2,056 3,323 71,610	58,116 185 658 10,582 5,197 1,947 3,438 74,805	59,831 185 683 11,111 5,697 1,855 3,559 73,093	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days Payable turnover days Profitability (%) ROE	0.1 1.2 121 41 196	0.1 1.6 105 43 145	1.6 115 40 150	1.6 115 40 155	1.7 115 40 155
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants Other non-current liabilities Total liabilities	38,490 202 551 12,469 7,527 2,196 2,747	42,069 185 622 11,084 5,697 2,183 3,204	54,011 185 635 10,075 4,697 2,056 3,323	58,116 185 658 10,582 5,197 1,947 3,438	59,831 185 683 11,111 5,697 1,855 3,559	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days Payable turnover days Profitability (%)	0.1 1.2 121 41 196	0.1 1.6 105 43 145	1.6 115 40 150	1.6 115 40 155	1.7 115 40 155
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants Other non-current liabilities Total liabilities Share capital	38,490 202 551 12,469 7,527 2,196 2,747 61,602	42,069 185 622 11,084 5,697 2,183 3,204 67,772	54,011 185 635 10,075 4,697 2,056 3,323 71,610	58,116 185 658 10,582 5,197 1,947 3,438 74,805	59,831 185 683 11,111 5,697 1,855 3,559 73,093	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days Payable turnover days Profitability (%) ROE	0.1 1.2 121 41 196	0.1 1.6 105 43 145	1.6 115 40 150	1.6 115 40 155	1.7 115 40 155
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants Other non-current liabilities Total liabilities Share capital Reserves	38,490 202 551 12,469 7,527 2,196 2,747 61,602	42,069 185 622 11,084 5,697 2,183 3,204 67,772	54,011 185 635 10,075 4,697 2,056 3,323 71,610	58,116 185 658 10,582 5,197 1,947 3,438 74,805	59,831 185 683 11,111 5,697 1,855 3,559 73,093	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days Payable turnover days Profitability (%) ROE	0.1 1.2 121 41 196	0.1 1.6 105 43 145	1.6 115 40 150	1.6 115 40 155	1.7 115 40 155
Account payables Tax payable Other current liabilities Non-current liabilities Bank borrowings Government Grants Other non-current liabilities	38,490 202 551 12,469 7,527 2,196 2,747 61,602 10,371 79,943	42,069 185 622 11,084 5,697 2,183 3,204 67,772 10,487 102,802	54,011 185 635 10,075 4,697 2,056 3,323 71,610 10,518 106,859 8,270	58,116 185 658 10,582 5,197 1,947 3,438 74,805 10,528 111,607	59,831 185 683 11,111 5,697 1,855 3,559 73,093 10,528 117,546 8,255	Balance sheet ratio Net cash/total equity (x) Current ratio (x) Receivable turnover days Inventory turnover days Payable turnover days Profitability (%) ROE ROA	0.1 1.2 121 41 196	0.1 1.6 105 43 145	1.6 115 40 150	1.6 115 40 155	

Source: Company data, CMBIGM estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY
Stock with potential return of over 15% over next 12 months

HOLD
SELL
Stock with potential return of +15% to -10% over next 12 months

Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.